**Appendix Table C7. Time to event outcomes: Treatment, Ewing’s tumors**

| **Study (Investigator, country, year)** | **Record Number** | **Group (N)** | **Outcome** | **Med (mos)** | **2 yr** | **5 yr** |
| --- | --- | --- | --- | --- | --- | --- |
| Costa, USA, 2008 | 1710 | 1 | 73 + months |   |   |   |
| Drabko, Poland 2005 | 6680 | 21 |   | 24 mos (13-59 mos) | HSCT in CR .68not in CR <.10 |   |
| Fazekas, Austria, 2008 | 2720 | 1 |   |   |   |   |
| Hara , Japan 1998 | 17950 | 3 | DOD 3 mosA with D 25+ mosA NED 59+ |   |   |   |
| Harimaya, Japan, 2003 | 9850 | 2 | A without D 67+ monthsDOD from recurrent tumor at 28 mos |   |   |   |
| Kasper, Germany, 2006 | 2570 | 5 | A NED 93+ mosA NED 70+A NED 59+A NED 46+DOD 30 months |   |   |   |
| Kogawa, Japan, 2004 | 8410 | 1 | 60 months + |   |   |   |
| Koscielniak Germany 2005 | 7860 | 1 |   |   |   |   |
| Lucas, USA 2008 | 2450 | 1 | 9 months + with disease |   |   |   |
| Lucidarme, France, 1998 | 17610 | 3 | 1 tx DOD 2 mos (n=1) of PD2 txs DOD 7 mos after 2nd tx (?)2 txs A NED 28+ mos after first tx |   |   |   |
| Meyers, USA, 2001 | 13670 |   |   |   |   |   |
| Navid, US and Canada, 2006 | 5930 | HSCTDOD n=2 at 27 and 28 mosA NED n=3 at median 67 mos (57-73) |   |   |   |   |
| Numata, Japan, 2002 | 12130 | 1 | 50+ months |   |   |   |
| Oberlin, France, 2008 | 46850 | <15 yrs |   |   |   | 49% |
| Ozkaynak, USA 1998 | 18540 | 15 |   |   |   |   |
| Pession, Italy, 1999 | 16120 | 3 | DOD 7 monthsANED 58+A w D 53+ |   |   |   |
| Prete, Italy 1998 | 17210 | 17 |   | 15 (1-40 mos) | 70% |   |
| Tanaka, Japan, 2002 | 11770 |   | n=1 DOD 19 mosn=5 A NED median 57 mos (42-90 mos) |   |   |   |
| Ilari, Italy, 2010 | 2230 | 24 | 7 year OS  |   |   | 64% (95%CI 38-81) (7 year OS) |
| Kwon, Korea, 2010 | 2268 | 1 | DOD 11 months |   |   |   |
| Ladenstein, Austria, France, UK, Switzerland, Netherlands, Germany, Sweden | 2270 | 99 | OS |   |   | mean .46SD 0.05 (3 year OS) |

**Appendix Table C7. Time to event outcomes: Treatment, Ewing’s tumors Continued**

| **Study (Investigator, country,** **year)** | **Record Number** | **Group (N)** | **Outcome\_2** | **Med (mos)\_2** | **2 yr\_2** | **3 yr\_2** | **5 yr\_2** | **Outcome\_3** | **Med (mos)\_3** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Burdach, Germany, 2003 | 10030 |   | EFS in <=17 yrs old | 32% +/- 11% with single40% +/- 13% with tandem |   |   |   |   |   |
| .Burke, USA 2007 | 4060 |   | tandem group NED n=4 after mean f/u of 6.25 yrs (3-10 yrs)DOD n=2 at 0.3 and 3.2 yrs |   |   |   |   | group single tx DOD at .5 yrs |   |
| Costa, USA, 2008 | 1710 | 1 |   |   |   |   |   |   |   |
| Drabko, Poland 2005 | 6680 | 21 | DFS |   | in CR .63 and not in CR 0 |   |   |   |   |
| Fazekas, Austria, 2008 | 2720 | 1 | DFS | relapsed 4 mos after HSCT (non-pulm); died after palliative CT |   |   |   |   |   |
| Hawkins, USA 2000 | 15360 |   | EFS (n=16) |   |   | 36% |   | EFS | grp 1 A NED: 66.7 % median 42 mos (27-66)PD 33.3% median 12 mos (6.3-17)grp 2: PD/DOD 28.6 % median 6.7 mos (0.1-26)NED/DOC n=2 (one at 9.6 months and one 31 mos after a 2nd HSCT (allo after auto) for MDS that the pt had prior to the auto tx |
| Kasper, Germany, 2006 | 2570 | 5 |   |   |   |   |   |   |   |
| Kogawa, Japan, 2004 | 8410 | 1 | DFS | 60+ months |   |   |   |   |   |
| Koscielniak Germany 2005 | 7860 | 1 | PFS | after allo 3.5 yrs |   |   |   |   |  PFS after tandem 8 mos |
| Laws, Germany, 2003 | 9450 |   | DFS | 30 mos and 6 mos |   |   |   |   |   |
| Lucas, USA 2008 | 2450 | 1 |   |   |   |   |   |   |   |
| Lucidarme, France, 1998 | 17610 | 3 |   |   |   |   |   |   |   |
| Meyers, USA, 2001 | 13670 |   | EFS |   | 20% |   |   |   |   |
| Navid, US and Canada, 2006 | 5930 | HSCTDOD n=2 at 27 and 28 mosA NED n=3 at median 67 mos (57-73) | no HSCTDOD n=2 @ 10 and 16 monthsA NED n=2 @ 73 and 80 months |   |   |   |   |   |   |
| Numata, Japan, 2002 | 12130 | 1 | DFS | 50 + months |   |   |   |   |   |
| Oberlin, France, 2008 | 46850 | <15 yrs | EFS |   |   |   | 46% |   |   |
| Ozkaynak, USA 1998 | 18540 | 15 | EFS |   |   | 51% (for pts in 1st remission 66% +/- 19%; for 2nd remission 37%) |   |   |   |
| Pession, Italy, 1999 | 16120 | 3 |   | DOD 7 monthsANED 58+A w D 53+ |   |   |   |   |   |
| Prete, Italy 1998 | 17210 | 17 | EFS |   | 63% |   |   |   |   |
| Tanaka, Japan, 2002 | 11770 |   | DFS | n=4 median 48.5 mos (31-74)n=1 NED at 79 mos |   |   |   |   |   |
| Diaz, Spain, 2010 | 2135 | 47 | PFS 56% +/- 4% with a median followup of 92 months for survivors (range 6-168 months) | by localized vs mets at dxPFS for pts with local dz:78% +/- 8% and for mets 27% +/- 10% |   |   |  |  |  |
| Ilari, Italy, 2010 | 2230 | 24 | 7 year EFS61% (95%CI 36-79) |  |  |  |  |  |  |
| Ladenstein, Austria, France, UK, Switzerland, Netherlands, Germany, Sweden | 2270 | 99 | 3 year EFS |  |  | mean 0.40SD 0.05 |  |  |  |